|
May 7
|
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
|
|
Apr 25
|
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
|
|
Apr 19
|
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
|
|
Apr 9
|
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
|
|
Apr 9
|
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
|
|
Apr 1
|
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
|
|
Mar 31
|
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
|
|
Mar 26
|
30 Countries with the Lowest Depression Rates
|
|
Mar 11
|
Vistagen to Present at Stifel 2024 Virtual CNS Days
|
|
Feb 6
|
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
|
|
Feb 1
|
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
|
|
Dec 29
|
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
|
|
Dec 27
|
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
|
|
Dec 20
|
11 Most Promising Psychedelic Stocks According to Hedge Funds
|
|
Nov 29
|
Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week
|
|
Nov 8
|
Vistagen to Present at Stifel 2023 Healthcare Conference
|
|
Nov 7
|
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
|
|
Nov 6
|
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
|
|
Aug 22
|
Vistagen Appoints Cindy Anderson as Chief Financial Officer
|
|
Jun 28
|
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
|